We have confirmed the report, demonstrating an increase in the specific activity of p60c-src protein-tyrosine kinase as found in human colon carcinoma cell lines. Ten colon carcinoma cell lines were examined and all were found to exhibit dramatic increase in p60c-src kinase activity, as compared to colon control lines. The oncogenic potential of c-src may be activated by a decrease in the phosphorylation state of the Tyr 527 residue, or by one or more mutations in the gene.
The specific aims of this Phase I proposal are (i) to determine whether there is a decrease in the activity of a protein-tyrosine kinase which phosphorylates the Tyr 527 site in p60c-src; (ii) to determine whether there is an increase in the activity of a phospho-tyrosyl protein phosphatase which dephosphorylates the p60c-src Tyr 527 site; and (iii) to determine whether one or more mutations in the src genome are responsible for the activation of p60c-src, and if so, to map such a site(s). In Phase II we propose to purify to homogeneity the specific protein responsible for c-src activation in human colon carcinomas and generate monoclonal antibodies against this protein species. These antibodies could potentially be diagnostic reagents for detection of human colon carcinomas.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43CA048614-01
Application #
3492110
Study Section
(SSS)
Project Start
1988-09-30
Project End
1989-06-30
Budget Start
1988-09-30
Budget End
1989-06-30
Support Year
1
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Osi Pharmaceuticals, Inc.
Department
Type
DUNS #
City
Uniondale
State
NY
Country
United States
Zip Code
11553